What testosterone gels are available in the UK?
Testosterone Gel UK: Testogel vs Tostran vs Testavan
TL;DR — key facts
3 gels
8 nmol/L
2–4 weeks
Title
What is testosterone gel and what's it used for?
Title
Treatment comparison
| Testogel 16.2mg/g | Tostran 20mg/g | Testavan 20mg/g | |
|---|---|---|---|
| Manufacturer | Besins Healthcare | ADVANZ Pharma | Simple Pharma |
| Formulation | Pump dispenser | Canister pump | Applicator pump |
| Application site | Shoulders & upper arms only | Abdomen or inner thighs | Upper arm & shoulder (via applicator) |
| Starting dose | 40.5mg (2 pumps) | 60mg (3 pumps) | 23mg (1 pump) |
| Max daily dose | 81mg | 80mg | 69mg |
| Transfer risk |
Moderate
|
Lower
|
Lowest
|
| Suitable for women | ✗ Too high concentration | ✓ Yes — at low dose | Not recommended |
| NHS availability | ✓ Yes | ✓ Yes | ✓ Yes |
| Best for | Most widely prescribed — familiar to GPs | Active mornings; women at low dose; longer canister supply | Men with children or partners — hands-free reduces transfer |
Testogel 16.2mg/g
Most prescribed
Manufacturer
Besins Healthcare
Apply to
Shoulders & upper arms only
Starting dose
40.5mg — 2 pumps daily
Max dose
81mg daily
Transfer risk
Moderate
Women
✗ Too high concentration
NHS
✓ Available
Tostran 20mg/g
Women-suitable
Manufacturer
ADVANZ Pharma
Apply to
Abdomen or inner thighs
Starting dose
60mg — 3 pumps daily
Max dose
80mg daily
Transfer risk
Lower
Women
✓ Yes — low dose
NHS
✓ Available
Testavan 20mg/g
Lowest transfer risk
Manufacturer
Simple Pharma
Apply to
Upper arm & shoulder via applicator
Starting dose
23mg — 1 pump daily
Max dose
69mg daily
Transfer risk
Lowest — hands-free
Women
Not recommended
NHS
✓ Available
Note: Testim (testosterone 1% gel) was discontinued in the UK in December 2023. AndroGel and Axiron are US products — they are not licensed or available in the UK. Always follow your prescriber's formulation-specific application instructions as sites and doses differ between products.
Sources: EMC Summaries of Product Characteristics — Testogel 16.2mg/g (Besins Healthcare, 2023); Tostran 20mg/g (ADVANZ Pharma, 2023); Testavan 20mg/g (Simple Pharma, 2022). NICE BNF testosterone prescribing guidance, accessed June 2026.
Testogel 16.2mg/g pump
Tostran 20mg/g
Testavan 20mg/g
Title
Who qualifies for testosterone gel in the UK?
8 nmol/L
8–15 nmol/L
2×
NHS eligibility
NHS criteria for testosterone gel — where do you sit?
What you need before NHS treatment begins
Two fasting morning blood tests — taken between 7–11am on separate occasions. Testosterone fluctuates throughout the day and between days — a single low reading is not diagnostic.
Clinical symptoms confirmed — biochemical deficiency alone is not enough. You must also have symptoms such as reduced libido, fatigue, erectile dysfunction, or loss of muscle mass.
Other causes ruled out — GPs will first consider sleep problems, obesity, stress, alcohol, thyroid issues, and depression before referring for TRT.
No prostate or breast cancer — absolute contraindication. Testosterone may stimulate the growth of hormone-sensitive tumours.
Not trying to conceive — testosterone gel suppresses sperm production. Discuss alternatives with your prescriber if fertility is a consideration.
Free testosterone matters — the NHS typically measures total testosterone only. Low free testosterone with normal total testosterone (due to high SHBG) can still cause symptoms but is rarely tested in primary care.
If your GP refuses: Ask for the clinical reason in writing. Request a referral to endocrinology or urology — this is your right under the NHS Constitution. If your reading was borderline, ask to retest. If all NHS routes fail, a CQC-registered private clinic is a clinically reasonable next step.
NHS 2026 update: Recent NICE guidance (2024) and BSSM 2022 guidelines have streamlined access. The NHS now handles straightforward hypogonadism cases in primary care more frequently — waiting times are shorter than two years ago. If your total testosterone is clearly below 8 nmol/L with symptoms, the NHS route is viable and free.
Sources: BSSM Guidelines for Testosterone Deficiency (2022) · NICE BNF testosterone prescribing guidance (accessed June 2026) · EAU Guidelines on Sexual and Reproductive Health (2026) · Society for Endocrinology UK guidance on androgen replacement in males.
Title
NHS vs private: honest comparison for 2026
Go NHS if
Go Private If
Cost guide
2026 private TRT cost breakdown — what to expect
| Item | Typical cost | Frequency | Notes |
|---|---|---|---|
| Initial consultation Private clinic — CQC registered | £150–300 | One-off | Includes review of blood results and treatment plan |
| Testosterone gel Testogel, Tostran or Testavan | £30–60 | Monthly | Medication cost — varies by formulation and dose |
| Ongoing monitoring Private clinic review | £50–100 | Every 3–6 months | Prescription renewal + clinical review |
| Home blood test panel Testosterone, FBC, PSA, LFTs | £40–80 | Every 3–6 months | Required for safe monitoring — some clinics include this |
| Estimated monthly total Ongoing after first 3 months | £60–120 | Per month | Gel + amortised monitoring and blood test costs |
| NHS prescription If eligible via GP or specialist | £9.90 | Per item | Standard NHS prescription charge — 2026 rate. Free if exempt. |
Initial consultation
One-off
Cost
£150–300
Notes
CQC-registered clinic — includes blood results review and treatment plan
Testosterone gel
Monthly
Cost
£30–60 / month
Notes
Testogel, Tostran or Testavan — varies by formulation and dose
Ongoing monitoring
Every 3–6 months
Cost
£50–100
Notes
Private clinic review — prescription renewal and clinical check
Home blood test panel
Every 3–6 months
Cost
£40–80
Notes
Testosterone, FBC, PSA, LFTs — some clinics include this in their fee
Est. monthly total
Ongoing
Cost
£60–120 / month
Notes
Gel + amortised monitoring and blood test costs after first 3 months
NHS prescription
Per item
Cost
£9.90
Notes
Standard NHS prescription charge — 2026 rate. Free if exempt (under 16, over 60, certain conditions).
Prices are indicative based on mid-2026 UK private clinic market rates. Costs vary between providers — always confirm the full fee structure including monitoring and blood tests before committing to a clinic. Main CQC-registered UK private TRT providers include Optimale, Balance My Hormones, Fountain TRT, Leger Clinic, and Numan.
Sources: UK private TRT clinic published pricing, June 2026. NHS prescription charge rates — NHS England 2026. Costs are estimates and subject to change.
Title
How to use testosterone gel correctly
Side effects and monitoring
Monitoring schedule
Skin reactions Common
Redness or dryness at application site — usually mild, settles within weeks. Rotate sites to reduce irritation.If persistent, try a different formulation or application site.
Polycythaemia Monitor closely
Raised red blood cell count — haematocrit must stay below 54%. Affects 5–10% significantly.Dose reduction or cessation required if exceeded. Increases clot risk.
Transfer risk Prevention key
Can transfer to partners and children before gel dries — causes virilisation in women, premature puberty in children.Always cover site with clothing. Testavan has lowest risk — hands-free applicator.
Fertility Important
Suppresses sperm production — not suitable for men trying to conceive.Recovery after stopping can take months. Discuss before starting.
Sleep apnoea Caution
Can worsen existing sleep-disordered breathing or trigger new onset.Report worsening snoring or daytime sleepiness to your prescriber.
Cardiovascular Ongoing debate
TRAVERSE trial data reassuring for confirmed hypogonadism — no increased cardiovascular risk vs placebo.Risk higher with polycythaemia. Discuss individual risk with prescriber.
Baseline
Before starting — testosterone, FBC, haematocrit, PSA (men over 40), LFTs, lipids
3 months
First check — testosterone levels and haematocrit. Morning test, before day's application.
6 months
Full panel — testosterone, FBC, PSA, LFTs, cardiovascular risk assessment
Annually
Ongoing — full panel repeated every 12 months for the duration of treatment
Always test in the morning before that day's gel application. A blood test taken after applying the gel will show artificially elevated levels and give a misleading result.
Testosterone gel vs other TRT options — which is right for you?
| Type | Frequency | Hormone peaks | Transfer risk | NHS | Private |
|---|---|---|---|---|---|
| Gel Testogel, Tostran, Testavan | Daily | Low — steady | Yes — cover site | ✓ Yes | ✓ Yes |
| Injection Nebido, Sustanon, Testosterone E | Every 1–14 weeks | High (short ester) / Low (Nebido) | ✓ None | ✓ Yes | ✓ Yes |
| Patch Androderm | Daily | Low — steady | ✓ Minimal | Limited | ✓ Yes |
| Pellet implant Testopel | Every 3–6 months | Very low — sustained | ✓ None | ✗ Rare | ✓ Yes |
GelRecommended start
Frequency
Daily application
Peaks
Low — steady levels
Transfer risk
Yes — cover site
NHS
✓ Available
InjectionEvery 1–14 weeks
Frequency
Every 1–14 weeks depending on ester
Peaks
High (short) / Low (Nebido)
Transfer risk
✓ None
NHS
✓ Available
PatchDaily
Frequency
Once daily — changed each day
Peaks
Low — steady levels
Transfer risk
✓ Minimal
NHS
Limited availability
Pellet implantEvery 3–6 months
Frequency
Minor procedure every 3–6 months
Peaks
Very low — sustained
Transfer risk
✓ None
NHS
✗ Rarely available
Gel suits you if...
You prefer daily routine control over your dose
You're new to TRT and want easy dose adjustment
You're sensitive to hormone peaks and troughs
You want to avoid needles entirely
Consider alternatives if...
Your gel absorption is poor after 6 weeks
You have skin conditions at application sites
You find daily application impractical long-term
You live with young children (or try Testavan)
Gel is not automatically the best option for everyone — the right formulation depends on your lifestyle, living situation, skin type, and whether you absorb transdermally well. Your prescriber should discuss all options before defaulting to gel.
Sources: BSSM Guidelines for Testosterone Deficiency (2022) · NICE BNF testosterone prescribing (accessed June 2026) · EAU Guidelines on Sexual and Reproductive Health (2026) · TRAVERSE trial cardiovascular outcomes data (2023).